# The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

> **NCT04069819** · NA · COMPLETED · sponsor: **Sadat City University** · enrollment: 80 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Cilostazol 50 MG Oral Tablet
- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04069819
- **Lead sponsor:** Sadat City University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04069819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04069819, "The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04069819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*